Hypertrophic Cardiomyopathy Market to be Driven by the Emergence of Novel Pharmacotherapies & Gene-directed Approaches at a 22.24% CAGR During the…

LAS VEGAS, Aug. 12, 2021 /PRNewswire/ -- DelveInsight's "Hypertrophic Cardiomyopathy (HCM) Market" report provides a thorough comprehension of the Hypertrophic Cardiomyopathy historical and forecasted epidemiology and the Hypertrophic Cardiomyopathy market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Hypertrophic Cardiomyopathy market report also proffers an analysis of the current Hypertrophic Cardiomyopathy treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Some of the necessary takeaways from the Hypertrophic Cardiomyopathy Market Research Report

For further information on Market Impact by Therapies, visit: Hypertrophic Cardiomyopathy Drugs Market Analysis

Hypertrophic Cardiomyopathy (HCM) is a heterogeneous myocardial disease, most often caused by autosomal dominant sarcomeric gene mutations, representing the most common monogenic cardiomyopathy in humans.

DelveInsight estimates that the total prevalent cases of Hypertrophic Cardiomyopathywere 1,054,281 in the 7MM in 2018, which is expected to increase by 2030.

The Hypertrophic Cardiomyopathy Market Analysis Reportprovides historical as well as forecasted epidemiological analysis segmented into:

Get a complete epidemiological segmentation breakdown @ Hypertrophic Cardiomyopathy Epidemiological Analysis

Hypertrophic Cardiomyopathy Treatment Market

The primary revenue-generating components of the Hypertrophic Cardiomyopathy treatment market can be broadly classified into the following therapeutic classes: Beta-blockers, calcium antagonists, ACEI/ARBs, anti-arrhythmic drugs (AADs), antiplatelet drugs, and anticoagulant drugs. Beta-blockers are the most popular and effective agents employed, generating significant revenue. Presently, atenolol, nadolol, bisoprolol, and metoprolol are some frequently used beta-blockers. While calcium antagonists are considered in intolerant patients or have contraindications to beta-blockers, angiotensin-converting enzyme inhibitors (ACEi), or angiotensin receptor blockers (ARBs), mainly target those patient segments suffering from concomitant systemic hypertension.

Current or potential targets of Hypertrophic Cardiomyopathy pharmacologic therapies cover a wide range of pathways. Each has its limitations as they compete to address the high unmet needs associated with the disease. Current medical therapy presents with systemic side-effects and inadequate or often variable efficacy. Treatment failure means resorting to surgical or other procedural interventions.

Hypertrophic Cardiomyopathy Pipeline Therapies

Mavacamten, a leading asset of MyoKardio and Bristol Myers Squibb (BMS), is one such candidate expected to enter the Hypertrophic Cardiomyopathy market within the first half of the forecast period [20212030]. It is an allosteric inhibitor of cardiac myosin under Phase III clinical trial (EXPLORER) for Hypertrophic obstructive cardiomyopathy (HOCM) patients and Phase II for hypertrophic nonobstructive cardiomyopathy (HNCM) patients. In its Phase II PIONEER-HCM trial, mavacamten demonstrated its efficacy in reducing HCM symptoms and partial normalization of cardiac functions, either as a monotherapy or co-administered with background medication like beta-blockers (BBs). The advantages offered by mavacamten will ensure its easy acceptance and steady market uptake post-approval since surveys indicate that physicians weigh more on functional improvement and obstruction than other indicators.

The other major cardiac myosin inhibitor candidate that can emerge as a game-changer in the coming years is CK-3773274 (CK-274), developed by Cytokinetics. It is a novel, oral, small-molecule cardiac myosin inhibitor designed to reduce the hyper-contractility associated with HCM currently in Phase II trials to treat patients with Hypertrophic obstructive cardiomyopathy (HOCM). A notable advantage that might eventually lend an upper hand to CK-274, in the long run, is that it has a shorter half-life than its predecessor. This would facilitate easier dosing changes in the event of a side-effect. The eventual nature and rate of market uptake if and when it gets approved will require close monitoring in the coming years.

LCZ-696, which Novartis is developing, combines a neprilysin inhibitor and an angiotensin II receptor blocker. The drug is currently in the Phase II stage of development to treat hypertrophic nonobstructive cardiomyopathy (HNCM). It is speculated to evolve as another Hypertrophic Cardiomyopathy treatment alternative in the coming years.

Concluding thoughts on Hypertrophic Cardiomyopathy Market Growth

Over the past six decades, few pharmacological studies have been completed in Hypertrophic Cardiomyopathy. Most have been small, with the majority comprising nonrandomized cohorts with no long-term follow-up. However, they have helped advance the understanding of therapeutic targets, although many recent drug trials have failed. The only silver lining seems to be the large amount of promise that the myosin inhibitor has offered. In a nutshell, it can be summed up that mavacamten should prove clinically effective and safe following long-term therapy in a more extensive and more diverse population; it would represent a much-anticipated development within the overall Hypertrophic Cardiomyopathy treatment landscape. Moreover, if the drug were to realize its potential as a disease-modifying therapy in younger individuals and severely affected Hypertrophic Cardiomyopathy patients, it would represent a significant milestone in the area of inherited cardiomyopathies. In addition, a robust pipeline and improved biomarker identification led treatment targets will significantly boost the overall Hypertrophic Cardiomyopathy market revenue generation during the forecast period [20212030] across the 7MM.

Scope of the Hypertrophic Cardiomyopathy Market Insight Report

Request for a Webex demo of the report @ Hypertrophic Cardiomyopathy Therapeutics Market

Table of Contents

1

Hypertrophic Cardiomyopathy Key Insights

2

Hypertrophic Cardiomyopathy Report Introduction

3

Hypertrophic Cardiomyopathy Market Overview at a Glance

4

Executive Summary of Hypertrophic Cardiomyopathy

5

Hypertrophic Cardiomyopathy Disease Background and Overview

6

Hypertrophic Cardiomyopathy Epidemiology and Patient Population

7

Country Wise-Epidemiology of Hypertrophic Cardiomyopathy

7.1

The United States

7.2

EU5 Countries

7.2.1

Germany

7.2.2

France

7.2.3

Italy

7.2.4

Spain

7.2.5

The United Kingdom

7.3

Japan

8

Hypertrophic Cardiomyopathy Treatment and Management

9

Hypertrophic Cardiomyopathy Patient Journey

10

Hypertrophic Cardiomyopathy Case Reports

11

Hypertrophic Cardiomyopathy Emerging Therapies

11.1

Mavacamten: Bristol Myers Squibb

11.2

CK-274: Cytokinetics

11.3

LCZ696: Novartis

12

Organizations Contributing Towards Hypertrophic Cardiomyopathy

13

Hypertrophic Cardiomyopathy 7MM Market Analysis

13.1

The United States Hypertrophic Cardiomyopathy Market Size

13.2

EU-5 Hypertrophic Cardiomyopathy Market Size

13.2.1

Germany Market Size

13.2.2

France Market Size

13.2.3

Italy Market Size

13.2.4

Spain Market Size

13.2.5

The United Kingdom Market Size

13.2.3

Japan Hypertrophic Cardiomyopathy Market Size

14

KOL Views

15

Hypertrophic Cardiomyopathy Market Drivers

16

Hypertrophic Cardiomyopathy Market Barriers

17

Hypertrophic Cardiomyopathy SWOT Analysis

18

Hypertrophic Cardiomyopathy Unmet Needs

19

Appendix

20

DelveInsight Capabilities

21

Disclaimer

22

Read the rest here:
Hypertrophic Cardiomyopathy Market to be Driven by the Emergence of Novel Pharmacotherapies & Gene-directed Approaches at a 22.24% CAGR During the...